Transmedics Group Inc
Research Transmedics Group Inc (TMDX) on Bullrun: market cap USD 3.24B, P/E 24.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTMDX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 3.24B
- P/E24.3
- Financial periodQ2 2026
- RevenueUSD 189.95M
- Net incomeUSD 14.68M
- Free cash flowUSD 10.22M
- Gross margin59.6%
Valuation Snapshot
latest market cap is USD 3.24B; P/E is 24.3.
Peer valuation comparison
Latest P/E is 24.35x versus a Healthcare sector median of 24.46x.
Latest P/E is 24.35x versus a United States median of 24.87x (2.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 605.49M | USD 190.30M | USD 133.59M | 59.9% | 4.87 | USD 488.87M | USD 10.00M | USD 473.10M |
| FY2024 | USD 441.54M | USD 35.50M | -USD 80.94M | 59.4% | 1.01 | USD 337.15M | USD 518.29M | USD 228.60M |
| FY2023 | USD 241.62M | -USD 25.00M | -USD 164.88M | 63.8% | -0.77 | USD 394.81M | USD 515.95M | USD 137.20M |
| FY2022 | USD 93.46M | -USD 36.20M | -USD 57.72M | 69.8% | -1.23 | USD 201.18M | USD 58.70M | USD 187.38M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.24B | 24.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.17B | 25.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.10B | 61.7 | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.58B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.97B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 532.49M | n/a | n/a | n/a |
About Transmedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Transmedics Group Inc's market cap?
Transmedics Group Inc's market capitalization is USD 3.24B.
What is Transmedics Group Inc's P/E ratio?
Transmedics Group Inc's price-to-earnings (P/E) ratio is 24.3.
What does Transmedics Group Inc do?
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.